Sommadossi Jean-Pierre's Form 4 filing
Atea Pharmaceuticals, Inc. (AVIR) · filed Sep 19, 2024
- Accession no.
- 0000950170-24-108233
- Filed
- Sep 19, 2024
- Trade date
- Sep 17-19, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $234.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sommadossi Jean-PierreCIK 0001296995 | Director, Officer (President, CEO, and Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2024 | Common Stock | SSaleDisposed | −33,941 | $4.05 | −$137,461.05 | 5,890,053 | Indirect | |
| Sep 18, 2024 | Common Stock | SSaleDisposed | −22,187 | $4.03 | −$89,413.61 | 5,867,866 | Indirect | |
| Sep 19, 2024 | Common Stock | SSaleDisposed | −1,841 | $4.00 | −$7,364 | 5,866,025 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.